Agenda For Change - Frequently Asked Questions (PDF 293 KB)

Agenda For Change - Frequently Asked Questions

Consultant Contract 2004 - Frequently Asked Questions (PDF 180 KB)

Consultant Contract 2004 - Frequently Asked Questions

Spearhead Health Inequalities Intervention Tool: frequently asked questions

This document answers some common questions about the use of the Spearhead Health Inequalities Intervention Tool.

Health inequalities intervention tool frequently asked questions

This document answers some common questions about the use of the Health inequalities intervention tool.

Cervical screening: Frequently asked questions (FAQs)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively. The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years. The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. These FAQs answer the most common and important queries in relation to HPV and the new screening process, and were distributed to all GPs in Northern Ireland. They can be downloaded as a PDF from this website.

Early Years Home Childcare Approval Scheme FAQ (PDF 40.2KB)

Early Years Home Childcare Approval Scheme - frequently asked questions

Proposed Model for Reference Pricing and Generic Substitution

Proposed Model for Reference Pricing and Generic Substitution Click here to download PDF 137KB   Click here to download the Frequently Asked Questions PDF 23KB

The Establishment of Hospital Groups as a transition to Independent Hospital Trusts

This is the Report on the Establishment of Hospital Groups as a Transition to Independent Hospital Trusts, as approved by Government on 14 May 2013. Click here to download The Establishment of Hospital Groups as a transition to Independent Hospital Trusts PDF 5.59MB Click here to download Securing the Future of Smaller Hospitals: A Framework for Development PDF 401KB Click here to download Frequently Asked Questions PDF 1.19MB  

Your guide to Understanding Alzheimer's Disease and other dementias

��The purpose of this booklet is to give you general information about Alzheimer's Disease and other dementias, and to highlight their early signs and symptoms.It offers a number of tools that can be helpful in establishing whether you or someone you care for is experiencing memory problems, and there is a diary at the back of this book to help track and record various changes that you or the person you love maybe experiencing.This booklet also contains details of what steps to take next if you are concerned about someone, how a diagnosis is made, what to do if you or someone close is diagnosed with Alzheimer's Disease, and outlines the various treatments that are available.Understanding Alzheimer's Disease also focuses on the importance of the role of the carer, explains carer stress, and offers some useful suggestions for reducing the stress that can build up when caring for someone full-time.It is hoped this booklet will give you answers to the more frequently asked questions and therefore give you a better understanding of Alzheimer's Disease and dementia.��

Flood Guidance

Public Health Agency flood guidance. There are a few precautions to be aware of when dealing with flooding, which should help prevent additional health problems. This factsheet also includes a section answering frequently asked questions.

Northern Ireland AAA Screening Programme: Professional information pack

The Northern Ireland Abdominal Aortic Aneurysm (AAA) Screening Programme began in June 2012 and offers AAA screening to all men in their 65th year in Northern Ireland.The aim of the AAA screening programme is to reduce AAA-related mortality by providing systematic, population-based screening. There is evidence of a significant reduction (45%) in mortality from AAA in those men aged between 65 and 79 years who undergo ultrasound screening. Men older than 65 years will be able to opt into the programme and request screening through the central screening office.There is also evidence of the long-term cost-effectiveness of AAA screening in men and further evidence that the early mortality benefit from screening is maintained.The items available for download here were in the professional information pack that was sent out to all GPs, GP practice managers and pharmacies prior to the launch of the programme.The invitation leaflet is sent out to all eligible men with the letter inviting them to screening.�The results leaflets are for men diagnosed with a small, medium or large AAA. The relevant result leaflet is given to men directly after their scan.�The poster was sent out to all GPs, GP practice managers and pharmacies in the run-up to the launch of the programme as a means of raising awareness.The information sheet outlines the structure of the programme, the screening process and the primary care that follows for those men diagnosed with an AAA. It also highlights the risk factors and has stats on AAA prevalence.The frequently asked questions address issues relating to all aspects of the programme: what is an AAA, roll-out of the programme, the screening process, the scan itself, the possible results, the available treatment, and how personal information is used.